Loading...

© 2026 MedXY

Contact us About us Privacy Policy MedXY story

MedXY AI/MedXY News/Tag: heart failure

MedXY News

EnglishTag

heart failure

159 · 20 / page

Ask MedXY AI

type 2 diabetes clinical trial heart failure immunotherapy obesity atrial fibrillation cardiovascular risk biomarkers Cardiology clinical trials critical care Hypertension oncology public health artificial intelligence Alzheimer's disease breast cancer diabetes type 1 diabetes cardiovascular disease chronic kidney disease nutrition

Latest news

Tag

Elevated Natriuretic Peptides: A Potent Predictor of Heart Failure and Mortality in Asymptomatic Diabetes

CardiologyDiabetes Mellitusheart failure

Elevated Natriuretic Peptides: A Potent Predictor of Heart Failure and Mortality in Asymptomatic Diabetes

By MedXY|Dec 26, 2025

A large-scale cohort study demonstrates that screening natriuretic peptide levels in individuals with type 1 or type 2 diabetes significantly predicts incident heart failure and death, advocating for routine biomarker-based risk stratificat

Intensive Lifestyle Intervention Reduces HFpEF Risk in High-Risk Diabetes: The Prescriptive Power of NT-proBNP

Cardiologyheart failurelifestyle intervention

Intensive Lifestyle Intervention Reduces HFpEF Risk in High-Risk Diabetes: The Prescriptive Power of NT-proBNP

By MedXY|Dec 26, 2025

A post-hoc analysis of the Look AHEAD trial demonstrates that NT-proBNP levels can identify patients with type 2 diabetes who benefit most from intensive lifestyle interventions. ILI significantly reduced HFpEF risk in those with elevated o

Finerenone and Hypotension Risk in Heart Failure: Evidence from the FINEARTS-HF Trial

CardiologyCardiologyfinerenone

Finerenone and Hypotension Risk in Heart Failure: Evidence from the FINEARTS-HF Trial

By MedXY|Dec 26, 2025

This analysis of the FINEARTS-HF trial identifies that while finerenone increases hypotension risk in HFmrEF and HFpEF patients, its clinical benefits persist. The study highlights key predictors of hypotension, such as low baseline blood p

Sacubitril-Valsartan Shows Biological Activity in Chagasic Heart Failure: Insights from the ANSWER-HF Trial

CardiologyChagas diseaseheart failure

Sacubitril-Valsartan Shows Biological Activity in Chagasic Heart Failure: Insights from the ANSWER-HF Trial

By MedXY|Dec 25, 2025

The ANSWER-HF trial compared sacubitril-valsartan to enalapril in patients with Chagasic heart failure. Although the primary endpoint of LVEF improvement was not met at 6 months, significant reductions in NT-proBNP and a favorable win ratio

High-Sensitivity Troponin I: A Poor Predictor of Anthracycline-Induced Left Ventricular Dysfunction?

CardiologyanthracyclinesCardio-Oncology

High-Sensitivity Troponin I: A Poor Predictor of Anthracycline-Induced Left Ventricular Dysfunction?

By MedXY|Dec 25, 2025

The Cardiac CARE trial reveals that high-sensitivity cardiac troponin I levels do not correlate with cumulative anthracycline dose and only weakly predict subsequent declines in left ventricular function, challenging existing risk-stratific

Vutrisiran Redefines the Therapeutic Landscape for Transthyretin Amyloidosis with Cardiomyopathy: Comprehensive Insights from the HELIOS-B Trial

CardiologyATTR-CMheart failure

Vutrisiran Redefines the Therapeutic Landscape for Transthyretin Amyloidosis with Cardiomyopathy: Comprehensive Insights from the HELIOS-B Trial

By MedXY|Dec 25, 2025

The HELIOS-B trial demonstrates that vutrisiran significantly improves clinical outcomes, stabilizes cardiac biomarkers, preserves cardiac structure, and enhances the quality of life in patients with transthyretin amyloidosis with cardiomyo

Redefining Severity in Tricuspid Regurgitation: Why CMR-Derived Regurgitant Fraction and Liver Mapping Are the New Prognostic Gold Standards

CardiologyCardiac Magnetic Resonanceheart failure

Redefining Severity in Tricuspid Regurgitation: Why CMR-Derived Regurgitant Fraction and Liver Mapping Are the New Prognostic Gold Standards

By MedXY|Dec 25, 2025

A landmark study in Circulation reveals that CMR-quantified tricuspid regurgitant fraction (TRF) ≥20% significantly increases mortality risk, while liver extracellular volume (L-ECV) mapping provides a novel, potent biomarker for systemic c

Beyond Traditional Risk Scores: How Preclinical Measures Refine Heart Failure Prediction in the ARIC Study

Cardiologycardiac biomarkersheart failure

Beyond Traditional Risk Scores: How Preclinical Measures Refine Heart Failure Prediction in the ARIC Study

By MedXY|Dec 24, 2025

Recent findings from the ARIC study reveal that integrating cardiac biomarkers and echocardiography with the PREVENT-HF score significantly enhances the prediction of incident heart failure, identifying high-risk individuals who traditional

A Unified High-Sensitivity Cardiac Troponin I Threshold of 80 ng/L for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy

Cardiologyheart failurerisk stratification

A Unified High-Sensitivity Cardiac Troponin I Threshold of 80 ng/L for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy

By MedXY|Dec 24, 2025

This multicenter study identifies high-sensitivity cardiac troponin I (hs-cTnI) as a potent, independent predictor of mortality in wild-type transthyretin amyloid cardiomyopathy. A universal threshold of 80 ng/L, integrated with natriuretic

Heart Failure Mortality: The Resilient Challenge in an Era of Declining Cardiovascular Deaths

CardiologyCardiovascular MortalityDiabetes Mellitus

Heart Failure Mortality: The Resilient Challenge in an Era of Declining Cardiovascular Deaths

By MedXY|Dec 20, 2025

This multi-national analysis of 2.92 million deaths highlights a concerning trend: while coronary and stroke mortality have plummeted, heart failure mortality remains stagnant or rising, with people with diabetes bearing a disproportionate

Artificial Intelligence-Enabled Prediction of Heart Failure Risk From Single-Lead Electrocardiograms: A Multinational Cohort Review

AIartificial intelligenceECG

Artificial Intelligence-Enabled Prediction of Heart Failure Risk From Single-Lead Electrocardiograms: A Multinational Cohort Review

By MedXY|Dec 5, 2025

This review evaluates AI algorithms predicting heart failure risk from noisy single-lead ECGs, synthesizing evidence from large multinational cohorts, highlighting improved risk stratification with AI-ECG models beyond traditional clinical

Sudden Death Drives Excess Mortality in HFmrEF/HFpEF with EF <50% — Insights from FINEARTS‑HF

Cardiologyfinerenoneheart failure

Sudden Death Drives Excess Mortality in HFmrEF/HFpEF with EF <50% — Insights from FINEARTS‑HF

By MedXY|Dec 4, 2025

In the FINEARTS‑HF trial, cardiovascular deaths comprised half of fatalities in HF with EF ≥40%, with sudden death accounting for the largest share — especially when EF was <50%. Finerenone did not clearly reduce cause‑specific mortality

Comprehensive Summary of the FINEARTS-HF Trial Results on Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Cardiologyejection fractionFINEARTS-HF

Comprehensive Summary of the FINEARTS-HF Trial Results on Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

By MedXY|Dec 3, 2025

The FINEARTS-HF trial demonstrates finerenone’s efficacy and safety in reducing heart failure events, improving symptoms, and lowering new-onset diabetes risk, with consistent benefits across sex, ejection fraction ranges, frailty levels, a

Prioritizing SGLT2 Inhibitors Over MRAs as Third-Line Therapy in HFrEF? Nationwide Cohort Shows Lower Mortality with SGLT2 Initiation

Cardiologyheart failuremineralocorticoid receptor antagonists

Prioritizing SGLT2 Inhibitors Over MRAs as Third-Line Therapy in HFrEF? Nationwide Cohort Shows Lower Mortality with SGLT2 Initiation

By MedXY|Dec 2, 2025

A Danish nationwide cohort study found that initiating SGLT2 inhibitors rather than mineralocorticoid receptor antagonists (MRAs) as the third foundational therapy after RASI and beta‑blocker in HFrEF was associated with lower all‑cause and

Declining Kidney Function Often Precedes Heart Failure Hospitalization in HFrEF — Track eGFR Slopes, Not Just Thresholds

Cardiologycardiorenal syndromeheart failure

Declining Kidney Function Often Precedes Heart Failure Hospitalization in HFrEF — Track eGFR Slopes, Not Just Thresholds

By MedXY|Nov 29, 2025

In HFrEF, eGFR often falls progressively for up to a year before heart-failure hospitalization or death. Monitoring eGFR trajectories provides earlier risk signals than single cut-offs and may identify patients for closer decongestion or th

Comprehensive Review of the EMPEROR-Preserved Trial: Efficacy and Safety of Empagliflozin in Heart Failure with Preserved Ejection Fraction

Cardiologyempagliflozinheart failure

Comprehensive Review of the EMPEROR-Preserved Trial: Efficacy and Safety of Empagliflozin in Heart Failure with Preserved Ejection Fraction

By MedXY|Nov 28, 2025

This review synthesizes the pivotal EMPEROR-Preserved Trial results, highlighting empagliflozin’s efficacy in reducing heart failure outcomes in patients with preserved ejection fraction.

Intracoronary Wharton’s Jelly Mesenchymal Stem Cells After STEMI Reduce Incident Heart Failure: Phase 3 PREVENT-TAHA8 Results

Cardiologyheart failuremyocardial infarction

Intracoronary Wharton’s Jelly Mesenchymal Stem Cells After STEMI Reduce Incident Heart Failure: Phase 3 PREVENT-TAHA8 Results

By MedXY|Nov 21, 2025

A phase 3 randomized trial found intracoronary infusion of allogeneic Wharton’s jelly mesenchymal stem cells (WJ-MSCs) after STEMI reduced new-onset heart failure and HF readmissions and improved LVEF versus standard care over a median 33-m

Mobile Integrated Health vs Transitions of Care in Heart Failure: Insights from the Mighty-Heart Trial

Cardiologyheart failureHospital readmissions

Mobile Integrated Health vs Transitions of Care in Heart Failure: Insights from the Mighty-Heart Trial

By MedXY|Nov 18, 2025

A large clinical trial compared Mobile Integrated Health with standard care coordination for heart failure patients after hospital discharge, finding no significant overall benefits but highlighting potential age-related effects.

Cardiotropic AAV Gene Therapy (AB-1002) Shows Early Safety and Signals of Efficacy in Phase 1 Heart Failure Trial

Cardiologyheart failure

Cardiotropic AAV Gene Therapy (AB-1002) Shows Early Safety and Signals of Efficacy in Phase 1 Heart Failure Trial

By MedXY|Nov 12, 2025

Phase 1 study of AB-1002 (cardiotropic AAV delivering I-1c) in 11 patients with nonischemic HFrEF showed feasibility, no treatment-attributed SAEs, transient LFT elevations at higher dose, and preliminary signals of improved LVEF and NYHA c

Warm and Cold Risks: How Temperature Variations Impact Mortality in Swedish Heart Failure Patients

Cardiologyheart failureMortality

Warm and Cold Risks: How Temperature Variations Impact Mortality in Swedish Heart Failure Patients

By MedXY|Oct 24, 2025

This study reveals that both low and high ambient temperatures significantly increase mortality risk among Swedish heart failure patients, highlighting the need for climate adaptation strategies in high-latitude regions.

Prev 1 4 5 6 7 8 Next

Ask MedXY AI

Most popular

Intimate Health

Five Benefits for Women Continuing Sexual Activity After Menopause

Intimate Health

Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It

How often should a couple have sex?

Intimate Health

Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure

Intimate Health

What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities